Kentucky Medicaid does not cover Wegovy or Zepbound for weight loss

Kentucky Medicaid does not cover GLP-1 drugs for weight loss. A state law in effect since April 14, 2026 bars the Department for Medicaid Services and its managed care plans from covering prescription drugs prescribed primarily for weight loss, and the Medicaid pharmacy criteria exclude drugs used for weight loss. Wegovy and Zepbound are covered only for other approved uses, with prior authorization.12314

Kentucky Medicaid uses one preferred drug list and one set of prior authorization criteria for fee-for-service and managed care members. GLP-1 approvals last 6 months, and drugs used for weight loss are excluded.36789

• Diabetes GLP-1s (Mounjaro, Ozempic pen, Trulicity, Victoza): a type 2 diabetes diagnosis in chart notes from the past 12 months and an A1c of 6.5 or higher, no personal or family history of medullary thyroid carcinoma or MEN 2, no other GLP-1 or DPP-4 drug at the same time, and a dose within the FDA maximum for diabetes.
• Renewal of a diabetes GLP-1 needs an A1c from the past 6 months and the prescriber's statement that the patient has been evaluated for safety and is responding to therapy.
• Non-preferred diabetes GLP-1s (Rybelsus, Ozempic tablets, exenatide, liraglutide): the same criteria plus a 3-month trial and failure, allergy, contraindication or intolerance of 2 preferred drugs.
• Wegovy for cardiovascular risk: age 45 or older, a documented heart attack, stroke or symptomatic peripheral arterial disease, optimized lipid-lowering therapy plus another cardiovascular drug, a BMI of 27 or more, use with a reduced-calorie diet and more physical activity, and no type 2 diabetes or A1c of 6.5% or higher.
• Wegovy injection for MASH: age 18 or older, MASH with F2 to F3 fibrosis confirmed by biopsy or a noninvasive test, no type 2 diabetes or cirrhosis, a trial of diet, exercise and lifestyle changes, and a gastroenterologist or hepatologist prescribing or consulted.
• Zepbound for obstructive sleep apnea: age 18 or older, moderate to severe sleep apnea confirmed by a sleep study, a BMI of 30 or more, a 3-month trial of a CPAP, APAP or BiPAP device, a sleep specialist or other specialist prescribing or consulted, and no diabetes.
• GLP-1 drugs are limited to two brand switches a year.

Coverage for other uses the FDA has approved:

• Wegovy (injection), reduction of the risk of major adverse cardiovascular events in adults 45 or older with a BMI of 27 or more and established cardiovascular disease, without type 2 diabetes: Covered with prior authorization7
• Wegovy tablets, reduction of the risk of major adverse cardiovascular events, under the same criteria as Wegovy injection (the MASH criteria exclude the tablet): Covered with prior authorization78
• Wegovy (injection), MASH with moderate to advanced (F2 to F3) liver fibrosis, without type 2 diabetes or cirrhosis (injection only): Covered with prior authorization8
• Zepbound, moderate to severe obstructive sleep apnea in adults with a BMI of 30 or more, without diabetes: Covered with prior authorization9

What changed, and when:

CMS BALANCE model: CMS's BALANCE model page names no participating states, and we found no Kentucky Department for Medicaid Services announcement that Kentucky has joined. State law now bars Medicaid coverage of drugs prescribed primarily for weight loss.151

All four KEHP plans for 2026 list a benefit for GLP-1 weight-loss drugs. In network, members pay the deductible and then 25% on the LivingWell CDHP and LivingWell PPO, or the deductible and then 30% on the LivingWell Basic CDHP and LivingWell HDHP. For 2026 the CDHP's share rose from 20% and the PPO's from a $40 copay. Coverage is limited to the CVS Caremark Value Formulary, and some drugs need prior authorization.1617

Pharmacy benefit: CVS Caremark (prescription drugs); Anthem (medical).

Marketplace (ACA) plans: Kentucky's essential health benefits benchmark plan, a UnitedHealthcare of Kentucky Choice Plus small-group plan, excludes any product dispensed for appetite suppression or weight loss.19

On the November 2026 Kentucky Medicaid preferred drug list, Mounjaro, Ozempic pen, Trulicity and Victoza are preferred with prior authorization, and Rybelsus, Ozempic tablets, exenatide and liraglutide are non-preferred. Each needs a documented type 2 diabetes diagnosis with an A1c of 6.5 or higher; a non-preferred drug also needs a 3-month trial of 2 preferred drugs.345

In 2025, Kentucky Medicaid paid for 273,652 GLP-1 prescriptions, $237.6 million before rebates: 59 per 1,000 residents, against 32 across the states and DC, 4th of 51.68 It reimbursed 8 GLP-1 products that year. Every state, ranked.

CMS hides counts under 11 in a quarter, so 33 rows count as zero here and the totals are a floor.

Part D still excludes drugs used for weight loss alone: the Part D drug definition excludes drugs and uses Medicaid may exclude under SSA §1927(d)(2), which lists agents used for weight loss. Part D plans can cover GLP-1s for type 2 diabetes, MACE risk reduction (Wegovy), moderate-to-severe obstructive sleep apnea (Zepbound) and noncirrhotic MASH with fibrosis (Wegovy). For weight loss alone, the Medicare GLP-1 Bridge demonstration (July 1, 2026 – Dec 31, 2027) gives eligible Part D enrollees Foundayo, Wegovy or Zepbound KwikPen for a $50 monthly copay, outside the Part D benefit. The BALANCE Model's Part D component is not launching in 2027.4344343530382333

• Medicare GLP-1 Bridge (demonstration) (active, from 2026-07-01): Runs July 1, 2026 to December 31, 2027 (extended). Outside the Part D benefit: $50 copay per one-month supply (28 or 30 days), Part D deductible does not apply, the copay does not count toward TrOOP, no low-income subsidy. Covers Foundayo, Wegovy (injection or tablet) and Zepbound KwikPen only (not Zepbound single-dose vials or pens). Eligibility: age 18+ and, when starting GLP-1 therapy, BMI ≥35; or BMI ≥30 with heart failure with preserved ejection fraction, uncontrolled hypertension, or CKD stage 3a+; or BMI ≥27 with prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible (their Part D plan may cover GLP-1s for those conditions). Prior authorization required; valid through Dec 31, 2027 unless the patient changes GLP-1s.3031322338394041423736
• BALANCE Model — Medicare Part D component (not launching in 2027; future implementation described by CMS only as 'potential'): Originally announced to launch in Part D in January 2027. CMS's BALANCE page FAQ now refers to 'the BALANCE Model not launching in Medicare in 2027' and extends the Bridge through Dec 31, 2027 to collect data 'ahead of potential implementation of BALANCE in Part D'. No new start date is published.252723

In 2024, Medicare Part D drug plans paid for 436,402 GLP-1 claims from prescribers in Kentucky, $525.2 million in total drug cost.69

The lowest price among the programs that ship to every state is WellMedr: $492 for 12 months ($41 a month); $99 month to month, fees in.73 Includes a sale seen on November 5, 2026; the price returns to the standing price when it ends. The cheapest programs, ranked, or every program, ranked on our score.

Prices are what each program charged at its own checkout, fees in, with the total due for the plan length first. Compounded GLP-1s are prepared by a pharmacy to a prescription, and they are not FDA-approved; the section on compounding explains what that means.

We may earn a commission when you sign up through some links. It never changes our order or scores. How we make money

29 more programs we rank ship to fewer than 50 states, or don’t say how many. We don’t record which states they leave out, so check Kentucky on their sites: Embody, Collective, SnagRx, Enhanced, Direct Meds, Gala Health, GobyMeds, CoreAge Rx, Maximus Tribe, Brightmeds, SkinnyRx, Willow, Strut Health, Enhance MD, LumiMeds, VivioMD, MEDGm, MyDrHank, Zevay, LevelsRx, Hume Care, ReadyRx, Hers, Luvo Health, Remedy Meds, Hims, DudeMeds, G-Plans and Found.

The makers also sell some brand-name GLP-1s for cash, at the same price in every state, with a prescription:

These are standing prices. The Zepbound and Wegovy rankings list each dose and the terms of each offer.

Compounded GLP-1s are prepared by a pharmacy to a prescription. They are not FDA-approved: the FDA doesn’t review their safety, effectiveness or quality before they’re sold, and they are not the same as Wegovy or Zepbound. Formulas can differ from one pharmacy to the next, and some add ingredients such as vitamin B12.7475 Compounding pharmacies are licensed and inspected by state boards of pharmacy; outsourcing facilities (503B) also register with the FDA and are inspected by it. The FDA can issue warning letters when either breaks rules on safety or sterility.

The FDA’s register lists 0 outsourcing facilities (503B) in Kentucky, as of November 6, 2026.70

FDA warning letters naming a GLP-1, sent to a company in Kentucky:71